Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases

ConditionsAmino-Acid Transport Disorder Primary Hyperparathyroidism Glioma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-90

SponsorTianjin Medical University

About this trial

To evaluate the potential usefulness of 11C/18F-MET/FET positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

adult patients (aged 18 years or order);

patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);

patients who had scheduled AATS PET/CT scan;

patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Disqualifiers

patients with non-malignant lesions;

patients with pregnancy;

the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Trial population

1. adult patients (aged 18 years or order); 2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); 3. patients who had scheduled AATS PET/CT scan; 4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

11C/18F-MET/FET
Diagnostic test
Each subject receive a single intravenous injection of 11C/18F-MET/FET, and undergo PET/CT imaging within the specificed time

Treatment groups

500 Participants

are divided into 1 treatment group

Group A: Single Group Assignment1 intervention

Trial outcomes

Primary outcomes

Standardized uptake value (SUV)

Standardized uptake value (SUV) of AATS for each target lesion of subject or suspected primary tumor or/and metastasis.

Time frame

30 days

Secondary outcomes

Diagnostic efficacy

The sensitivity, specificity and accuracy of AATS PET/CT were calculated.

Time frame

30 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tianjin Medical University

Lead sponsor

Tianjin Medical University General Hospital

Collaborator

Source ClinicalTrials.gov

Apply now